Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full |
| _version_ | 1819139993763840000 |
|---|---|
| author | Matthew E. Tenold Benjamin N. Moskoff David J. Benjamin Rasmus T. Hoeg Aaron S. Rosenberg Mehrdad Abedi Joseph M. Tuscano Joseph M. Tuscano Brian A. Jonas Brian A. Jonas |
| author_facet | Matthew E. Tenold Benjamin N. Moskoff David J. Benjamin Rasmus T. Hoeg Aaron S. Rosenberg Mehrdad Abedi Joseph M. Tuscano Joseph M. Tuscano Brian A. Jonas Brian A. Jonas |
| author_sort | Matthew E. Tenold |
| collection | DOAJ |
| description | Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML. |
| first_indexed | 2024-12-22T11:31:29Z |
| format | Article |
| id | doaj.art-952a0e9bb5b4475182416ad7275cd6bc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T11:31:29Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-952a0e9bb5b4475182416ad7275cd6bc2022-12-21T18:27:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.649209649209Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer CenterMatthew E. Tenold0Benjamin N. Moskoff1David J. Benjamin2Rasmus T. Hoeg3Aaron S. Rosenberg4Mehrdad Abedi5Joseph M. Tuscano6Joseph M. Tuscano7Brian A. Jonas8Brian A. Jonas9Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesPharmacy Department, University of California Davis School of Medicine, Sacramento, CA, United StatesDivision of Hematology and Oncology, Department of Internal Medicine, University of California, Irvine Medical Center, Orange, CA, United StatesDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesVeterans Administration Northern California Healthcare System, Sacramento, CA, United StatesDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United StatesVeterans Administration Northern California Healthcare System, Sacramento, CA, United StatesRelapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML.https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/fullacute myeloid leukemiavenetoclax (BCL-2 inhibitor)hypomethylating agentrelapsed/refractoryreal-world data |
| spellingShingle | Matthew E. Tenold Benjamin N. Moskoff David J. Benjamin Rasmus T. Hoeg Aaron S. Rosenberg Mehrdad Abedi Joseph M. Tuscano Joseph M. Tuscano Brian A. Jonas Brian A. Jonas Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center Frontiers in Oncology acute myeloid leukemia venetoclax (BCL-2 inhibitor) hypomethylating agent relapsed/refractory real-world data |
| title | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
| title_full | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
| title_fullStr | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
| title_full_unstemmed | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
| title_short | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
| title_sort | outcomes of adults with relapsed refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center |
| topic | acute myeloid leukemia venetoclax (BCL-2 inhibitor) hypomethylating agent relapsed/refractory real-world data |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full |
| work_keys_str_mv | AT matthewetenold outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT benjaminnmoskoff outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT davidjbenjamin outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT rasmusthoeg outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT aaronsrosenberg outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT mehrdadabedi outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT josephmtuscano outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT josephmtuscano outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT brianajonas outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT brianajonas outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter |